Latest Office News

Victory Metals has put a A$1.21 billion post-tax PFS value on North Stanmore, secured its mining lease and begun product qualification with potential offtake partners. The project remains pre-production, with DFS work, approvals, financing and metallurgical validation still ahead.

Wide Open Agriculture has completed the major physical steps in exiting its German manufacturing facility and is now testing four prospective Asian production partners. The transition could lower fixed costs, but commercial supply still depends on technical trials, partner selection and a definitive agreement.

Nutritional Growth Solutions has cut quarterly net operating cash outflow by 54% while completing its Sprout Organic acquisition just after quarter end. The enlarged group starts with US$1.613 million in cash, no borrowings and a substantially larger share base.

Nexalis Therapeutics ended September with $371,000 in cash, equivalent to just 0.9 quarters of funding at its recent operating burn. The company has settled its dispute with Linlithgow Family Office, but its clinical programs remain paused while it pursues R&D tax funding and a new capital raise.

Antilles Gold remains largely stalled in Cuba after its joint venture was designated a US Specially Designated National, with only site security continuing at Nueva Sabana. A conditional GEM deal could bring US$18 million and a path towards sanction relief, but the company ended September with just US$882,000 in cash.

Sunshine Metals has advanced three Queensland development threads, with Liontown’s preliminary study outlining $179.8 million in estimated net operating cashflow after capital and Mt Moss still targeting first gold in mid-2027. The gains come with a funding question, as the company held $15.2 million in cash at quarter-end and has a financing update due in November.

Optiscan has moved its InForm and InVue medical-imaging devices into formal US FDA review after a quarter of intensive regulatory and clinical work. The milestone comes with $11.093 million in cash and a reported 3.5 quarters of funding at the latest operating burn rate.

Silver Mines has entered the final stretch of the Bowdens approval process after reporting a 93.5 million ounce silver reserve, a completed A$26 million royalty consolidation and A$70 million of new funding. The project’s headline 26-year economics remain partly dependent on a Stage 2 design that is not yet at definitive feasibility level.

Alexium has lifted production efficiency and September revenue, but ended the quarter with only US$337,000 of cash and available funding. The company remains dependent on further shareholder loans while targeting positive operating cash flow in June 2027.

Doctor Care Anywhere’s Q3 revenue rose 16% to £11.3 million as its weight-management business delivered its first full quarter, lifting subscription revenue to 19% of the total. The unaudited update also shows modest consultation growth, higher cash and three new distribution partnerships.

Clinuvel has submitted NEURACTHEL Instant for regulatory review in three initial European Union markets, opening a potential pathway for its second pharmaceutical product. The decentralised review is expected to take 300 days, excluding clock stops, but the product is not yet approved anywhere.

ImpediMed lifted quarterly revenue and recurring revenue, but weaker-than-expected BCRL sales and a near-total sales team rebuild have put its path to cash-flow break-even under pressure. The company ended September with $11.6 million in cash and 4.7 quarters of funding at the quarter’s operating burn.